Abstract

Recent advances in small molecule kinase inhibitors have markedly improved patient survival in various types of cancer. Most of these successes can be attributed to the concept of “targeting driver oncogenes,” as in the case of tyrosine kinase inhibitors (i.e., EGFR inhibitors), but not in serine/threonine kinase inhibitors including CHK1 inhibitor. Further investigation of the underlying mechanisms is needed to identify synergistic interactions of CHK1 that would help prolong patient survival and improve their quality of life.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.